Ozempic vs. Mounjaro 2026: A1C, Weight Loss & Cost Compared
Ozempic and Mounjaro are the two GLP-1-class drugs that dominate Type 2 diabetes prescriptions in 2026 — and the head-to-head SURPASS-2 trial settled the molecule debate clinically: tirzepatide produced superior A1C reduction and superior weight loss vs. semaglutide. Mounjaro is the better drug on those two endpoints. But Ozempic has the longer track record, the SUSTAIN-6 cardiovascular outcomes data, and broader insurance coverage in 2026.
This comparison is for people deciding between branded Ozempic and branded Mounjaro for Type 2 diabetes — not weight loss (that's Wegovy vs. Zepbound). The eligibility and savings programs are different. The off-label weight-loss prescribing patterns are different. The clinical data is different.
We pulled real 2026 pricing, current savings-card mechanics, and SURPASS-2 head-to-head data to give you a clean comparison.
Ozempic vs. Mounjaro: side-by-side comparison
| Dimension | Ozempic | Mounjaro |
|---|---|---|
| Active ingredient | Semaglutide | Tirzepatide |
| Mechanism | GLP-1 receptor agonist | Dual GIP / GLP-1 agonist |
| FDA approval | December 2017 | May 2022 |
| Maker | Novo Nordisk | Eli Lilly |
| Indication | Type 2 diabetes | Type 2 diabetes |
| Avg. A1C reduction | 1.1–1.8% (SUSTAIN program) | 1.9–2.4% (SURPASS program) |
| Avg. weight loss | 9–14 lbs | 15–25 lbs |
| Cardiovascular evidence | SUSTAIN-6 — 26% MACE reduction | SURPASS-CVOT in progress |
| Doses available | 0.25 / 0.5 / 1.0 / 2.0 mg weekly | 2.5 / 5 / 7.5 / 10 / 12.5 / 15 mg weekly |
| Sister weight-loss drug | Wegovy (same molecule, higher dose) | Zepbound (same molecule, weight-loss label) |
| Common side effects | Nausea, constipation, GI | Nausea (slightly less), GI |
| Real-world track record | 8+ years | 3+ years |
If your A1C is the priority, Mounjaro wins on the head-to-head trial. If you have cardiovascular disease, Ozempic wins on the outcome data. Most people pay $25 either way.
Cost comparison: Ozempic vs. Mounjaro in 2026
Real 2026 prices from active programs across savings cards, manufacturer cash-pay channels, retail pharmacies, and compounded alternatives.
| Cost path | Ozempic | Mounjaro |
|---|---|---|
| Savings card (commercial insurance) | $25/mo | $25/mo |
| Manufacturer cash | $499/mo (NovoCare) | Through LillyDirect (variable) |
| Retail cash price | $998/mo | $1,069/mo |
| Compounded alternative | $179–$349/mo (semaglutide) | $249–$499/mo (tirzepatide) |
| Federal plan eligibility | Excluded for card; Medicare Part D covers | Excluded for card; Medicare Part D covers |
When to choose Ozempic vs. Mounjaro
Choose Ozempic if:
- ✓You have established cardiovascular disease and want SUSTAIN-6's 26% MACE reduction data behind you
- ✓You've been on a semaglutide pen successfully and don't want to switch molecules
- ✓Your insurance plan covers Ozempic but has Mounjaro on a higher tier
- ✓You prefer Novo Nordisk's pen design or have already started their savings card
Choose Mounjaro if:
- ✓Your A1C reduction goal is aggressive and the head-to-head data matters
- ✓You're losing weight as a secondary benefit and want maximum effect
- ✓Your insurance plan covers Mounjaro at a lower tier than Ozempic
- ✓You've had insufficient response to semaglutide and your clinician wants to try the dual GIP/GLP-1
Clinical evidence behind Ozempic vs. Mounjaro
SURPASS-2 (NEJM 2021): the only head-to-head trial. Tirzepatide (Mounjaro) produced significantly greater A1C reduction (-2.01% to -2.30% vs. -1.86% for semaglutide 1.0 mg) and weight loss (-7.6 to -11.2 kg vs. -5.7 kg) over 40 weeks in Type 2 diabetes patients. SUSTAIN-6 (NEJM 2016): semaglutide demonstrated a 26% relative risk reduction in major adverse cardiovascular events vs. placebo over 104 weeks in patients with established CV disease. Mounjaro's cardiovascular outcomes trial (SURPASS-CVOT) is ongoing.
Top providers that prescribe Ozempic or Mounjaro
Providers we've verified for clinically appropriate Ozempic or Mounjaro pathways. Pricing and availability vary by state and insurance.
Clinician + RD-led weight-loss program — insurance-friendly intake with personalized GLP-1 plans where appropriate.
- ✓ Clinician-led with registered dietitians on the care team
- ✓ Insurance-friendly intake — provider files coverage on your behalf
- ✓ Personalized plan covering nutrition, behavior, and Rx where appropriate
- − Slower first prescription than direct compounded programs (multi-week onboarding)
- − Pricing depends on insurance plan — outcomes vary
- − Pivot routing — CTA routes through our eligibility quiz
WeightWatchers-operated GLP-1 program — brand-name medications combined with the WW behavioral track.
- ✓ Operated by WeightWatchers — established consumer brand recognition
- ✓ Combines GLP-1 prescribing with the WW behavioral program
- ✓ Insurance-friendly intake with brand-name GLP-1 pathway
- − Brand-name GLP-1 pricing — premium without insurance coverage
- − WW behavioral program required for full benefit
- − Pivot routing — CTA routes through our eligibility quiz
Year-long coaching + GLP-1 metabolic program — brand-name medications with insurance pathway and behavior support.
- ✓ Coaching-led one-year metabolic program
- ✓ Combined GLP-1 prescribing + nutrition + behavior change support
- ✓ Insurance-coverage pathway included for eligible patients
- − 12-month program commitment — higher upfront vs. month-to-month competitors
- − Brand-name GLP-1 path — premium pricing without insurance
- − Pivot routing — CTA routes through our eligibility quiz
Ozempic vs. Mounjaro: frequently asked
Which is more effective, Ozempic or Mounjaro?
On the head-to-head SURPASS-2 trial, Mounjaro produced superior A1C reduction and weight loss. On long-term cardiovascular outcomes, Ozempic has SUSTAIN-6's 26% MACE reduction data — Mounjaro's CV trial is still in progress.
Is Mounjaro the same as Zepbound?
Same molecule (tirzepatide), different FDA-approved indication. Mounjaro is approved for Type 2 diabetes; Zepbound is approved for chronic weight management. The dose ranges and pen designs are similar but commercially distinct.
Is Ozempic the same as Wegovy?
Same molecule (semaglutide), different doses and FDA indications. Ozempic is approved for Type 2 diabetes (lower doses, up to 2.0 mg). Wegovy is approved for chronic weight management (higher doses, up to 2.4 mg).
Can I get Ozempic or Mounjaro for weight loss?
Both are sometimes prescribed off-label for weight loss, but neither is FDA-approved for that indication, and insurance coverage for off-label weight-loss prescribing is inconsistent. The on-label weight-loss equivalents are Wegovy (semaglutide) and Zepbound (tirzepatide).
Which has fewer side effects, Ozempic or Mounjaro?
Both cause GI side effects (nausea, constipation, reflux) that concentrate in the first 8 weeks and at each dose increase. Trial data suggests Mounjaro's dual GIP/GLP-1 mechanism produces slightly less GI distress for some patients, but the gap is small.
Can I switch from Ozempic to Mounjaro?
Yes, with clinician guidance. You restart at the new drug's starter dose (Mounjaro 2.5 mg) and titrate. There's no required washout period.
Do federal-plan patients (Medicare, Medicaid, VA) have access?
Federal plans don't allow manufacturer copay cards (federal anti-kickback statute), but Medicare Part D and most state Medicaid programs cover Ozempic and Mounjaro for the Type 2 diabetes indication.
Are compounded semaglutide and compounded tirzepatide alternatives to Ozempic and Mounjaro?
They contain the same active ingredients but aren't Ozempic or Mounjaro. They're prepared at licensed 503A or 503B pharmacies against individual prescriptions. Pricing is typically $179–$499/month all-in. Both molecules came off the FDA shortage list (semaglutide early 2025, tirzepatide late 2024).